meditoxin 200 units

The Taiwan Food and Drug Administration granted rights to Medytox to sell 100 and 200 units per kilogram vials of the Meditoxin, branded as Neuronx, in Taiwan. Medytox applied for authorization for its BTX product to the Taiwanese regulator in 2018.

The company has strengthened its presence in Taiwan by establishing Medytox Taiwan in partnership with Dynamic Medical Technologies (DMT), specializing in aesthetic lasers and light-based medical equipment.

With the recent authorization, Medytox and DMT will supply Meditoxin and launch hyaluronic acid (HA) dermal filler Neuramis Volume Lidocaine in Taiwan. The two partners also plan to advance to other Southeast Asian aesthetics markets.

Taiwan is an important base for entering Southeast Asian countries as a link for the smooth delivery of the company’s products to nearby countries, Medytox said, quoting a report by the Korea Trade-Investment Promotion Agency (KOTRA).

“The recent approval of Neuronox in Taiwan is significant as we have come to export BTX and HA fillers to the Taiwanese market,” a Medytox official said. “Taiwan, which is closely related to the overseas Chinese economy in Southeast Asia, could become a catalyst for our explosive growth in the Southeast Asian market. We will provide customized marketing along with DMT, which has unique capabilities in the Taiwanese medical aesthetics market.”

출처 : KBR(http://www.koreabiomed.com)